In this four-part series, Im excited to share my key recommendations to help support your practice
Lets be direct about what this means for consumers: nobody, not HIMS, not the compounding pharmacy, not the prescribing provider, has any idea what the actual plasma concentration of semaglutide is after a patient takes this pill
However, they noted that these findings need to be verified by studies involving other groups, including those taking GLP-1 drugs for obesity
This information helps you and your healthcare provider make informed decisions about dose adjustments
Glucagon receptor activation is thought to increase energy expenditure and promote fat breakdown (lipolysis), which may help explain the substantial weight loss observed in early-phase trials however, these mechanistic effects have not yet been fully characterised in humans and should be regarded as preliminary findings
Emerging research suggests that GLP-1 medications may help reduce addictive behaviors, including alcohol cravings and cigarette smoking